 On Dec. 15, the highly anticipated results of Guardant Health Inc.s GH , Financial pivotal DNA blood test trial were revealed, and the results fell short of expectations, causing the companys stock price to plummet 30. The test managed to detect just 83 of colorectal cancers and 13 of advanced adenomas a cancer precursor. 